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propriate timing and indications for beginning RRT. severity of illness and its effect on outcomes should pro-
mote a change in our paradigms for the appropriateCRRT achieved a higher rate of renal recovery. Intermit-
tent hemodialysis (IHD) provided inadequate azotemia selection of dialysis modality and its application for renal
control despite 5.2 treatments/week and failed to achieve support rather than replacement [3]. Our results also sup-
fluid goals in 28.8%. port the need for further research to establish standards
CRRT may be more feasible and better tolerated in for timing, indications, dose of dialysis, and then for an
unstable, highly catabolic/hypervolemic patients, and in individualized approach for management of acute renal
those with liver failure. IHD is cheaper, associated with failure before embarking on future randomized controlled
fewer bleeding complications, and can be used in patients trials. The Acute Dialysis Quality Initiative (ADQI) is an
who tolerate it (adjusting solute clearance). The role of initial attempt, which we hope will serve as a starting
hemofiltration in sepsis [2, 3] requires more data and point for future research and development of practice
identification of precise mechanism. guidelines in this field [4].
Mehta et al have contributed to the debate of CRRT
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proteins and implications forReply from the Author
We agree with Dr. Cuhaci that underlying severity of glomerular protein sieving inillness is a strong determinant of outcome from acute
renal failure requiring dialysis. As discussed in our article Fanconi syndrome
[1], the study was powered for an effect size of 20%
reduction in mortality (from 70% to 50%) and we did
not include hypotensive patients to avoid biasing the To the Editor: The calculations of glomerular sieving
coefficients in Fanconi syndrome by immunoassay [1]study in favor of continuous renal replacement therapy
(CRRT). We did not standardize timing and indication have not considered the effects of the relatively large
quantities of protein fragments [2] that arise by degrada-or dose of dialysis as these factors are not well defined
even today and were even less appreciated when the tion of filtered protein during renal passage [3, 4]. The
fragments do not arise in plasma of non-filtered kidneysstudy was initiated. Despite its limitations, we believe
that our study is still relevant to modern-day practice. nor are they at sufficient concentration in the circulation
to account for the matieral in urine [4]. Fragments areIt highlights the importance of standardizing an ap-
proach for dialysis in acute renal failure as there is wide not detected by immunoassays [5]. It is clear that any
estimation of protein glomerular sieving coefficient hasvariation in the timing and indications for dialysis and
choice of modality [2]. Recognition of the underlying to take into account these fragments. Furthermore, esti-
